Allelic loss at BRCA1, BRCA2, and adjacent loci in relation to TP53 abnormality in breast cancer

Su Ling Tseng, Jyh Cherng Yu, Chung Tai Yue, Shu Fen Chang, Tzu Ming Chang, Cheng-Wen Wu Lee, Chen Yang Shen*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

26 Scopus citations


Cells with abnormal TP53 lose cell cycle checkpoints, resulting in genomic instability and neoplastic transformation. However, the evidence linking the tumor-specific targets of genomic alteration to an abnormal TP53 is limited. The present study tested the hypothesis that TP53 abnormalities are correlated with an increased frequency of deletion of breast cancer susceptibility loci (17q and 13q) in breast carcinomas. Tumors from 90 patients were examined for TP53 abnormality and loss of heterozygosity (LOH) at 11 loci on 17q (17q11.2-21) and 13q (13q12-14), including the loci for BRCA1 and BRCA2. A higher frequency of LOH was consistently found at 17q or 13q loci in tumors with an abnormal TP53. The increased LOH in relation to TP53 abnormality was statistically significant at the BRCA1, D17S588, and D13S267 loci (P < 0.05) but not at the locus for 8RCA2 (P = 0.64). These observations imply a possible link between an abnormal TP53 and specific genomic deletions of breast cancer susceptibility loci, which may provide clues to the role of TP53 during breast tumorigenesis.

Original languageEnglish
Pages (from-to)377-382
Number of pages6
JournalGenes Chromosomes and Cancer
Issue number4
StatePublished - 1 Dec 1997


Dive into the research topics of 'Allelic loss at BRCA1, BRCA2, and adjacent loci in relation to TP53 abnormality in breast cancer'. Together they form a unique fingerprint.

Cite this